Всемирный Конгресс 2019
Программа

ФОКУС НА S065

Анализ продукта - Новое поколение сосудистых и пигментных IPL

Зал: Room 342 (level 3)
Дата: четверг 31 января 2019 в 08:30 до 09:30
Формат: АНАЛИЗ ПРОДУКТА > сравнительное некоммерческое исследование категории продуктов или устройств, представленных на рынке

Председатели

Доктор Anne LE PILLOUER

Дерматолог

Франция

Доктор Godfrey TOWN

PhD - Research

Великобритания

Лекции сессии

Время	Спикеры	Заголовок сессии	Абстракт	Номер
08:30	Доктор Godfrey TOWN	Introduction of the study and generalities	Посмотреть	77195
08:40	Richard BANKOWSKI	Round table with the participation of: Cynosure		77141
08:40	Ann WILD	Round table with the participation of: Lumenis		77143
08:40	Доктор Hugues CARTIER	Round table with the participation of: Candela		77145
08:40	Simone PARENTI	Round table with the participation of: DEKA		82075

Увидеть предыдущий зал (Room 253 (Level 2))

Перейти на следующую сессию

Рекомендуемые сессии

Светотерапия (IPL, UV, IR, LED...)

Доктор Godfrey TOWN

PhD - Research

Великобритания

Другие авторы : Dr Anne Le Pillouer Prost, Dermatologist, France

Introduction of the study and generalities

Objectives: The pulsed dye laser (PDL) has long been the treatment of choice for port wine stains (PWS) and other vascular abnormalities. The goal of this round-table discussion is to consider a new generation of intense pulsed light (IPL) devices and understand how and why they rival traditional pulsed dye laser treatment of vascular and pigmentary abnormalities.

Introduction: Efforts have been made by PDL manufacturers to extend the the laser wavelength from 585 nm to 595-600 nm to improve depth of penetration to allow deeper vessels to be targeted with less purpura. Longer pulse durations and the advent of epidermal cooling have permitted the use of higher fluences and greater patient comfort.
The use of IPL was first suggested in 1998 and in subsequent years, despite encouraging clinical data and modification of irradiation parameters including pulse duration, fluence and wavelength, IPL technology has so far failed to win-over the die-hard PDL user.

Materials / method: Four companies with recent and innovative claims for their intense pulsed light (IPL) technology will participate in a round-table discussion. Three industry representatives and one dermatologist will respond to selected company slides presented by the session chairs to explore novel technology advances to explore the clinical and scientific evidence for these advances.

Results: IPL technology innovations for vascular treatments include: dual band filtering to reject low absorption wavebands, Rhodamine-doped xenon lamp source to focus energy in the PDL waveband, sub-millisecond pulse durations to mimic the PDL pulse duration and manipulation of the spatial and temporal IPL pulse profile.

Conclusion: Evidence-based clinical and scientific results confirm that modified IPL technology can match PDL clinical outcomes and deliver a better side-effect profile than traditional PWS.